Epithelial damage is an important pathophysiologic feature of asthma. Bronchial epithelium damage results in release of growth factors such as transforming growth factor (TGF)-b 1 that may affect epithelial cell proliferation. The objective of our study is to evaluate the importance of TGF-b 1 in regulating epithelial cell repair in asthma. We evaluated the effect of TGF-b 1 on epidermal growth factor (EGF)-induced proliferation and downstream signaling in epithelial cells obtained from subjects with asthma compared with cells from healthy subjects. Cell proliferation was evaluated by bromodeoxyuridine incorporation. EGF receptor (EGFR), mitogen-activated protein kinase, TGF-b receptors, Smads, Smad anchor for receptor activation (SARA), and cyclin-dependant kinase inhibitors were evaluated by Western blot. TGF-b 1 and receptor expression were measured by RT-PCR and by enzyme-linked immunosorbent assay. Proliferation of epithelial cells at baseline and after EGF stimulation was significantly reduced in cells derived from subjects with asthma compared with cells obtained from healthy control subjects. EGF-induced ERK1/2 phosphorylation was reduced in epithelial cells from subjects with asthma compared with cells from healthy control subjects. This was paralleled with a reduced EGFR phosphorylation. Addition of TGF-b 1 significantly decreased EGF-induced cell proliferation. TGF-b 1 production was higher in asthmatic epithelial cells compared with normal cells. This was supported by a high expression of pSmad 3 and SARA in cells derived from individuals with asthma compared with normal subjects. Cycline-dependent kinase inhibitors were highly expressed in asthmatic compared with normal cells. Inhibition of TGF-b 1 signaling in asthmatic epithelial cells restored EGFR, ERK1/2 phosphorylation, and cell proliferation induced by EGF. Our results suggest that TGF-b restrains EGFR phosphorylation and downstream signaling in bronchial epithelial cells.
Epithelial damage is one of the many pathophysiologic features that has been observed even in mild asthma, but not in other pulmonary diseases such as chronic obstructive disease and chronic bronchitis (1) (2) (3) . There is a correlation between the desquamation of the epithelium and the degree of bronchial hyperreactivity (2) . Excessive epithelial damage can arise from an enhanced susceptibility to injury or an inadequate response to an environmental stimulus. Using a bicellular model of bronchial mucosa produced by tissue engineering, we showed that the asthmatic-derived epithelium loses the capacity to maintain an organized structure. This finding is in agreement with other observations reported in asthma and suggests that the asthmatic epithelium has an intrinsic abnormal function and an altered ability to repair (4) (5) (6) .
Restitution of a damaged epithelium is modulated by the extracellular matrix (ECM), integrins, and growth factors (7) . Epithelial cells produce a number of growth factors, including epidermal growth factor (EGF) and transforming growth factor-b (TGF-b), which play an important role in morphogenesis and repair. EGF stimulates cell proliferation, regulates cellular adhesion and motility, and enhances ECM production (8) . EGF exerts its biological functions via the epidermal growth factor receptor (EFGR), a member of the ErbB family of receptor tyrosine kinase (9) . Tyrosine phosphorylation of EGFR leads to activation of the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathways (10) . EGF and EGFR expression increases in asthmatic airways (11, 12) . The high level of EGFR expression in asthma is paradoxical, since it is not matched by an increased proliferation of the bronchial epithelium. Inhibition of EGFR activation slows epithelial repair but enhances the production of TGF-b in epithelial cell line (13) . TGF-btriggered signals are transduced by Smads, a family of proteins that serve as substrates for type I and II TGF-b receptors (TGFb-RI/TGFb-RII) in which the cytoplasmic domain possesses serine/ threonine kinase activity. The type I receptor recognizes and phosphorylates Smad2 and Smad3 which, in association with Smad4, form a complex that translocate to the nucleus. Other Smad proteins, such as SARA (Smad anchor for receptor activation) and Smad7 (inhibitor of Smad2/3 complex), are important effectors of TGF-b signaling. Treatment of bronchial epithelial cells with TGF-b increases the expression of p21, a cell cycle inhibitor (14) . There is increasing evidence that TGF-b is involved in the pathogenesis of asthma. Basal levels of TGF-b 1 are higher in the bronchoalveolar lavage (BAL) fluids of patients with asthma, and increase in response to allergen exposure (15) . In addition, the increased expression of TGF-b in the airways of individuals with asthma is correlated with disease severity and the degree of subepithelial fibrosis (16, 17) .
TGF-b may antagonize the effect of EGF on airway epithelial cell repair in asthma. Hence, specific intracellular signaling molecules coordinate proliferative and anti-proliferative signals and the balance of these molecules determines the normal or abnormal response of the epithelial cells to injury. In this study, we compared proliferation of bronchial epithelial cells obtained from subjects with asthma and from healthy control subjects at baseline and in presence of EGF and TGF-b 1 . We then evaluated TGF-b 1 and EGFR signaling in these cells.
MATERIALS AND METHODS

Epithelial Cell Culture
Seventeen volunteers (nine subjects with asthma and eight healthy control subjects), aged between 20 and 35 years, were recruited from the Asthma Clinic at Hô pital Laval (Quebec, PQ, Canada). The ethics committee of Hô pital Laval approved the study and all subjects gave written informed consent. The subjects with asthma were diagnosed according to the American Thoracic Society criteria (methacholine PC 20 , 8 mg/ml) and used only inhaled b 2 -agonists on demand (18) . Their mean FEV 1 was 85 6 3.1% and mean PC 20 was 4.0 6 2.2 mg/ml. None used inhaled or systemic corticosteroids. All subjects with asthma were nonsmokers, were atopic, and had skin test positive for house dust. Normal subjects (mean FEV 1 5 98.2 6 5.1% and mean PC 20 5 99.4 6 1.2 mg/ml) were nonatopic and nonsmokers with no history of asthma or systemic diseases.
Epithelial cells were isolated from bronchial biopsies obtained by bronchoscopy. Epithelial cells were characterized by immunofluorescence and flow cytometry using anti-cytokeratin antibody from Calbiochem (San Diego, CA). This identification confirmed the purity of the bronchial cell culture as we previously described (19) .
Bronchial epithelial cells were cultured in a combination of Dulbecco's modified Eagle's medium (DMEM) with Ham's F12 in a 3:1 proportion (Invitrogen, Burlington, ON, Canada), supplemented with 10 ng/ml human epidermal growth factor (Austral Biologicals, San Ramon, CA), 24.3 mg/ml adenine, 5 mg/ml crystallized bovine insulin, 5 mg/ml human transferrin, 2 3 10 29 M 3,39,59, triiodo-L-thyronin (Sigma Chemicals, St-Louis, MO), 0.4 mg/ml hydrocortisone (Calbiochem), 10 210 M cholera toxin (Sigma Chemicals), 10% fetal bovine serum (FBS) (Invitrogen), 100 U/ml penicillin G and streptomycin, and 25 mg/ml gentamicin (Sigma). The culture medium was changed three times a week.
Cell Proliferation
Cells were seeded (10,000 cells/well) in 96-well tissue culture cluster plates that were coated with a 500 mg/ml of collagen solution (Sigma) for 45 minutes and air-dried before each experiment. Cells were deprived of EGF for 1 day and treated with EGF 5 ng/ml; TGF-b 1 5 ng/ml; PD98059 50 mM, an inhibitor of ERK1/2 kinase; AG1478 3 mM (Calbiochem), a specific EGFR kinase inhibitor; or with SB431542 10 mM, a specific TGF-b receptor inhibitor. All doses were previously determined with a dose-response study. Twenty-three hours before harvesting cells, bromodeoxyuridine (BrdU) was added at a final concentration of 10 mM. Cell proliferation was measured using a cell proliferation colorimetric enzyme-linked immunosorbent assay (ELISA) commercial kit (Roche, Laval, PQ, Canada) following the manufacturer's instructions. The viability and the adherence of the cells were controlled.
Western Blots
Cells were cultured to near-confluence on collagen-coated culture flasks. Cells were FBS and EGF starved for 24 hours before stimulation. Cells were then stimulated with EGF 5 ng/ml in the presence or absence of TGF-b 1 5 ng/ml, PD98059 50 mM, AG1478 3 mM, or with SB431542 10 mM for 5 minutes to 24 hours depending on the experiment. After stimulation, cells were detached using cell scrapers and centrifuged.
Cell pellets were resuspended in lysis buffer containing 25 mM TrisHCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.1% SDS, 0.05% sodium deoxycholate, and 1% Triton X-100. Proteinase inhibitor PMSF 0.5 mM and phosphatase inhibitors NaF 10 mM and Na 3 VO 4 2 mM were added to the homogenized samples. After 1 hour of incubation at 48C, samples were centrifuged at > 12,000 3 g for 2 minutes. Supernatants were collected and stored at 2208C. Protein concentration was determined using the Bradford assay.
Equal amounts of total protein (20-40 mg) in reducing sample buffer (61.5 mM Tris, 2% SDS, 10% glycerol, 100 mM DTT) were boiled for 5 minutes and migrated using 4% stacking gel followed by 7%, 10%, or 12% acrylamide SDS-PAGE. Gels were transferred to PVDF membranes using a Tris-glycine refrigerated transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, 100 mM Na 3 VO 4 ) for 1 hour at 100 V. Blots were incubated overnight with the appropriate primary antibody. Membranes were washed and incubated for 1 hour in the appropriate peroxydaseconjugated secondary antibodies. Detection was performed using the ECL detection system (Amersham Pharmacia Biotech, Piscataway, NJ) according to the manufacturer's instructions. Luminescence was visualized by autoradiography.
The following antibodies and dilutions were used: anti-TGFb-RI, anti-TGFb-RII, anti-SARA, anti-p21 (1:500), anti-EGFR and antiSmad7 (1:200) (Santa Cruz biotechnology, Santa Cruz, CA). The anti-p15 (1:1,000) was from Transduction Laboratories (San Jose, CA). The anti-p27 (1:1,000) was from BD Biosciences Pharmingen (San Diego, CA). The anti-phosphorylated EGFR and the anti-Smad3 (1:1,000) were from Abcam (Cambridge, MA). The anti-phosphorylated Smad3 (1:1,000) was from Cell Signaling Technology (Danvers, MA). The anti-ERK1/2, and the anti-phosphorylated form of ERK1/2 (1:1,000), were from R&D Systems (Minneapolis, MN). Anti-b-actin (1:5,000) was from Sigma Chemicals. Peroxydase-conjugated secondary antibodies (1:1,000) were from Amersham Biosciences.
RT-PCR
Nonconfluent epithelial cells from subjects with asthma and from normal subjects were cultured on collagen-coated plates. Cells were cultured in 1% FBS supplemented medium for 24 hours. Total RNA was extracted using the RNeasy Mini Kit following the manufacturer's protocol (Qiagen, Mississauga, ON, Canada). RNA concentration was measured by the fluorescent dye Ribogreen RNA quantification reagent (Invitrogen). Total RNA (500 ng/sample) were denaturated at 658C for 10 minutes and incubated at 378C for 60 minutes, with the following mix: 0.5 mM dNTP, 0.25 mg/ml hexamer pd(N)6, 200 U MMLV-RT and 13 first-strand buffer (Invitrogen). TGF-b 1 mRNA was amplified by PCR with 30 cycles at an annealing temperature of 608C. TGF-b 1 primers (158 bp) were: 59-GCCCTGGACACCAACTATT-39 forward and 59-AGGCTCCAA ATGTAGGGG-39 reverse. GAPDH primers (221 bp) were: 59-ATG CAACGGATTTGGTCGTAT-39 forward and 59-TCTCCTCCTGGA AGATGGTG-39 reverse. TGF-b 1 mRNA was normalized to that of the corresponding housekeeping gene GAPDH as previously described (20) . After amplification, samples were analyzed on a 1% agarose gel. The relative intensities of the PCR products were measured by digitalized image on a Macintosh computer using the public domain program NIH image.
Total TGF-b 1
Epithelial cells from each normal subject and from each subject with asthma were seeded in collagen-coated 6-well plates (4 3 10 5 cells/well), EGF starved, and grown for 24 hours in 1% FBS supplemented medium. Cell culture supernatants were acidified with 1 N HCl for 10 minutes at ambient temperature and neutralized with 1.2 N NaOH/0.5 M HEPES before testing to ensure activation of total TGF-b 1 . Total TGF-b 1 was detected by ELISA using a commercial kit (R&D systems Inc.) following the manufacturer's instructions. Plates were read at 450 nm with a wavelength correction at 550 nm using a microplate reader (Molecular Devices Corp., Sunnyvale, CA). The minimum detectable level of TGF-b 1 was less than 5 pg/ml.
Active TGF-b PAI-1 Luciferase Assay
Mink lung epithelial cells (MLEC) were kindly provided by Dr. Rifkin (New York University Medical Center, New York, NY). These cells have been stably transfected with an 800-bp fragment (2799 to 171) of the 59 end of the human plasminogen activator inhibitor-1 (PAI-1) gene fused to the firefly luciferase reporter gene in a p19LUC-based vector containing the neomycin-resistance gene from pMAMneo (21) . Transfected MLECs were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, and 200 mg/ml G418 (Invitrogen). Active TGFb-containing samples were added directly to 1.6 3 10 4 cells and incubated for 16 hours. Cells were then washed and lysed in lysis buffer (25 mM Tris-phosphate pH 7.8, 2 mM DTT, 10% glycerol, 1% Triton X-100). Luciferase activity was measured with a Dynex 96-well plate luminometer (Dynex Technologies, Chantilly, VA).
Statistical Analysis
All experiments in this study were performed at least three times. Experimental values are given as means 6 SEM. To compare groups and conditions, the data were analyzed using a crossed-nested design. When interactions between groups and conditions were significant, each group was analyzed using a randomized block design. A posteriori multiple comparisons were performed using Tukey-Kramer test. Mean values 6 SEM of quantitative variables were used as representative measures. All reported P values were two-sided and were declared significant at 0.05 levels.
RESULTS
Proliferation of Epithelial Cells from Subjects with Asthma and from Healthy Control Subjects
We compared the baseline proliferation of epithelial cells from normal subjects and subjects with asthma. Figure 1 shows that proliferation levels were lower in asthmatic cells than healthy control cells (37.2 6 3.1% of normal epithelial cell proliferation, P , 0.0001). Viability of the cells was around 96% all the time in both cell populations. There was no diminution of adherence at different times of culture in asthmatic cells, which was around 82%.
Effect of TGF-b 1 on EGF-Induced Proliferation
We evaluated the role of EGF and TGF-b 1 on growth of epithelial cells from normal subjects and subjects with asthma. As seen in Figure 2A , EGF induced significant proliferation in both normal (161.5 6 8.8%, P , 0.001) and asthmatic cells (133.2 6 4.4%, P , 0.001). However, cell proliferation was significantly higher in normal compared with asthmatic cells (P 5 0.012). TGF-b 1 did not affect the baseline proliferation in either group. Also, TGF-b 1 significantly inhibited EGF-induced proliferation in both normal (69.4 6 8.8% inhibition, P , 0.001) and asthmatic (18.7 6 6.2% inhibition, P 5 0.026) cell populations. These results suggest that TGF-b 1 could disturb EGFR signaling pathway in epithelial cells.
EGFR Signaling in Epithelial Cells Isolated from Normal Subjects and from Subjects with Asthma
To ascertain the role of EGF-mediated EGFR activation in triggering ERK1/2 MAPK pathway, we preincubated epithelial cells with a specific EGFR tyrosine kinase inhibitor, AG1478, and with a specific ERK1/2 kinase inhibitor, PD98059, before EGF incubation and BrdU incorporation. Figure 2B shows that EGF-induced proliferation was blocked after incubation with AG1478 in both normal cells (79.7 6 4.5% of inhibition, P , 0.001) and asthmatic cells (34.8 6 11.9% of inhibition, P 5 0.004). Incubation of cells with PD98059 inhibited EGF-induced proliferation in normal cells (65.1 6 4.9% of inhibition, P , 0.001) but not in asthmatic cells (14.3 6 9.2% inhibition, P 5 0.11).
To confirm these results, we looked at EGFR and ERK1/2 phosphorylation levels. Phosphorylation was detected at 5 to 30 minutes after EGF exposure in nonconfluent normal cells and was maximal at 5 minutes for both pEGFR and pERK1/2 activation (data not shown). Figure 3A shows that at baseline, EGFR was overexpressed in asthmatic epithelial cells compared with normal epithelial cells. Stimulation with EGF showed that EGFR was phosphorylated at 5 minutes in normal epithelial cells. However, this phosphorylation was not detected in asthmatic cells. Time course of EGFR phosphorylation in asthmatic cells (until 1 h after EGF stimulation) confirmed the reduction of EGFR phosphorylation (data not shown). Stimulation with TGF-b 1 inhibited EGF-induced EGFR phosphorylation. Addition of a specific TGF-b receptor inhibitor, SB431542, restored EGF-induced phosphorylation in epithelial cells from both healthy control subjects and subjects with asthma ( Figure 3A) . (B) Cells obtained from normal subjects (NBEC; n 5 6) and from subjects with asthma (ABEC; n 5 6) were pre-treated for 45 minutes with AG1478 (3 mM; solid bars) or PD98059 (50 mM; shaded bars), and proliferation after EGF incubation was evaluated by BrdU incorporation. Open bars, EGF-stimulated cells. *P , 0.001, **P , 0.001 versus EGFstimulated NBEC, #P 5 0.004 versus EGF-stimulated ABEC.
ERK1/2 phosphorylation levels increased after 5 minutes of EGF exposure ( Figure 3B ) in normal cells but not in asthmatic cells. Moreover, TGF-b 1 inhibited EGF-induced ERK1/2 phosphorylation.
Expression of TGF-b 1 and its Receptor in Bronchial Epithelial Cells
TGF-b 1 mRNA was significantly overexpressed in asthmatic cells compared with healthy control cells (P 5 0.01), as shown in Figure  4A . Total TGF-b 1 protein levels were also measured in supernatants of cell culture by ELISA. Asthmatic epithelial cells produced significantly more TGF-b 1 (311.2 6 51.9 pg/ml) than normal cells (102.1 6 32.1 pg/ml; P 5 0.003) ( Figure 4B ). The active form of TGF-b was also assessed by a bioassay using mink lung epithelial cells transfected with a plasmid containing the luciferase reporter gene under the control of the PAI-1 promoter. Supernatants of asthmatic epithelial cells produced significantly more active TGF-b (36.5 6 3.1 pg/ml) than normal cells (20.5 6 3.5 pg/ml; P 5 0.02).
TGFb-RI and TGFb-RII were detected by Western blots in total protein extracts from epithelial cells. Figure 4C shows that TGFb-RI but not TGFb-RII was overexpressed in protein extracts from asthmatic cells. Results were normalized with bactin. The availability of large amounts of TGF-b 1 and the overexpression of its receptors in asthmatic cells could contribute to impaired EGF-induced proliferation.
Smad Pathway Expression in Bronchial Epithelial Cells
Asthmatic epithelial cells showed higher levels of phosphorylated Smad3 at baseline compared with normal control cells ( Figure  4D ). Phosphorylated Smad3 was induced by TGF-b 1 . Smad7, an inhibitor of Smads signaling pathway, seemed to be downregulated in asthmatic epithelial cells and not modulated by TGF-b 1 . Moreover, SARA, which helps anchor Smad2/3 complexes to the TGF-b receptor, was overexpressed in cells from subjects with asthma compared with cells from healthy control subjects.
Expression of Cyclin-Dependent Kinase Inhibitors in Bronchial Epithelial Cells
Epithelial cells from subjects with asthma had higher levels of cyclin-dependent kinase (cdk) inhibitors at baseline compared with epithelial cells from normal subjects ( Figure 5A ). TGF-b 1 induced the expression of p21, p15, and p27 in normal epithelial cells. This effect was less prominent in asthmatic cells due to the overall high expression levels. Densitometric analyses confirmed p21 overexpression in asthmatic cells (P 5 0.02) ( Figure 5B ). Inhibition of EGFR and ERK signaling with chemical inhibitors PD98050 and AG1478 had no effect on TGF-b-induced p27 expression ( Figure 5C ). This was also obtained for p15 and p21 (data not shown). Figure 6A shows that inhibition of TGF-b re-established EGFinduced ERK1/2 phosphorylation in both normal and asthmatic cells. EGF-induced cell proliferation of asthmatic cells was also recovered in the presence of TGF-b inhibitor ( Figure 6B ). Inhibition of the effect of endogenous TGF-b released by asthmatic epithelial cells induced a significant increase in EGF-induced proliferation (192.1 6 61.4% versus 128.6 6 5.1%, P 5 0.05 of EGF-induced proliferation). TGF-b inhibited EGF-induced proliferation. This effect was significantly reversed by the addition of TGF-b inhibitor in both healthy control cells and epithelial cells from subjects with asthma (168.5% and 166.2 6 28.7%; P 5 0.006 and P 5 0.04, respectively). Figure 6C shows that specific inhibition of TGF-b signaling can down-regulate TGF-b-induced p27 expression in both populations. 
Effect of TGF-b Receptor Inhibition on ERK1/2 Activation, Cell Proliferation, and cdk Inhibitor Expression
DISCUSSION
TGF-b has been implicated in the pathogenesis of asthma (17) . It has been hypothesized that an enhanced expression of TGF-b in the asthmatic airways may have an effect in the pathophysiology of the disease (22) . An excess of TGF-b can inhibit subsequent epithelial cell proliferation that is required during early wound healing (23) . However, the role of TGF-b 1 in human asthma is not completely understood. This growth factor has a wide range of biological functions, including cell proliferation, differentiation, hematopoiesis, apoptosis, tumorigenesis, migration, and extracellular matrix (ECM) production (24, 25) . TGF-b 1 is produced by many types of cells that are activated in the asthmatic response (26) . It is inhibitory for inflammatory cells such as T cells, B cells, dendritic cells, mast cells, and eosinophils, and also modifies the functions of structural cells such as bronchial epithelial cells, fibroblasts, and smooth muscle cells (27) . Our data support the role of TGF-b 1 as one of the main regulators of bronchial epithelial cell proliferation in patients with asthma. We demonstrated that epithelial cells derived from subjects with asthma produce significantly more active and latent TGF-b 1 than cells from healthy control subjects. This finding is consistent with what has been report by Hastie and coworkers (28) . Moreover, these cells express high level of TGFb-RI and phosphorylated Smad3, indicating that TGF-b 1 signaling is up-regulated in epithelial cells derived from subjects with asthma compared with cells from subjects without asthma. We also showed that asthmatic cells have a low expression of Smad7, an inhibitor of Smad2/3 complex phosphorylation, and high expression of SARA, an activator of Smad2/3 complex, which could help activating TGF-b 1 signaling pathway.
Cell proliferation is tightly regulated by a variety of cell cycle modulators in which cdk, an active kinase subunit of the cyclin/ cdk complexes, is a major regulator of the transition between the phases of cell cycle progression. Mitogen-dependent progression through the first gap phase (G1) and initiation of DNA synthesis (S phase) during the mammalian cell division cycle are cooperatively regulated by several classes of cyclin-dependent kinases whose activities are in turn constrained by cdk inhibitors (29) . INK4 proteins such as p15 specifically inhibit the catalytic subunits of CDK4 and CDK6. The INK4 proteins can be contrasted with more broadly acting inhibitors of the Cip/Kip family, including p21 and p27, both of which can bind to cyclin and cdk subunits. TGF-b 1 is known to induce the expression of these cdk inhibitors in different cell types (30) . Higher levels of TGFb 1 expression in asthmatic cells is matched with a strong overexpression of all three tested cdk inhibitors. Such high expression of cdk inhibitors could contribute in maintaining low rates of proliferation. Inhibition of EGFR or ERK signaling did not alter cdk inhibitor expression. This indicates that this constitutes a parallel pathway that may influence proliferation of epithelial cells in asthma.
Growth factor receptors are transmembrane receptor tyrosine kinases, and activation of these receptors increase tyrosine phosphorylation of multiple downstream proteins, which eventually leads to various biological responses. Previous studies demonstrated that total EGFR protein levels and EGF were highly expressed in asthmatic airways (11, 12, 26, 31) , contradicting low proliferation rates. Our data confirm that EGFR is overexpressed in primary epithelial cells derived from subjects with asthma compared with cells from normal control subjects. However, baseline EGFR activation was lower in asthmatic cells than in normal cells. Moreover, EGF stimulation did not induce EGFR phosphorylation in asthmatic cells. This nonresponse is not related to receptor mutation. Thus, we evaluated the sequence of EGFR in our cells and we did not show the presence of any mutation (personal communication). EGFR phosphorylation is an important step in downstream signaling and low phosphorylated EGFR/ total EGFR ratios in asthmatic cells that we observed could contribute to the low proliferation rates. Our data show that TGF-b 1 reduced the phosphorylation of EGFR and ERK1/2 in bronchial epithelial cells. Despite low levels of ERK1/2 activation in asthmatic epithelial cells after EGF treatment, TGF-b appears to retain the ability to inhibit ERK phosphorylation. Thus, inhibition of TGF-b 1 signaling by a specific inhibitor of TGF-b receptor kinase activity brings back EGF-induced EGFR and ERK1/2 phosphorylation, and improves proliferation of epithelial cells derived from subjects with asthma. Moreover, cdk inhibitors were reduced when TGF-b 1 was inhibited, which may contribute to the improvement of the proliferation. TGF-b reduced the phosphorylation of EGFR. It would be important in the next step to evaluate if this effect is mediated by suppression of Ras or activation of phosphatases.
Epithelial cell repair is dependent on the capacity of the cell to proliferate. In this study, we demonstrated that epithelial cells isolated from subjects with asthma have lower proliferation rates than cells isolated from normal subjects. We reported that high expression and signaling of TGF-b 1 in asthmatic cells leads to an overexpression of cdk inhibitors, reduction of EGF-induced proliferation, and EGFR phosphorylation. Imbalance between proliferative pathways and TGF-b pathway could explain the inability of the epithelium of asthmatic airways to repair properly. Corticosteroids, the cornerstone of asthma medication, have been shown to be ineffective to reduce the expression of TGF-b in the asthmatic airways (17) . Development of new strategies that will specifically target TGF-b could be useful to help repair airway epithelium in asthma.
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